Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Thomas E. Clancy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0949-4874; OpenAlex author ID A5087484173. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
122
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 4 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 30

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Quantitative Assessments of Shared Decision-Making for Pancreatic Cancer Surgery: A Scoping Review. Co-author DOI 10.1016/j.jss.2026.03.060↗
  4. Retraction: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2. Co-author DOI 10.1158/0008-5472.can-25-0887↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  6. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  7. Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocarcinoma: National Cancer Database Analysi… Co-author DOI 10.7759/cureus.73524↗
  8. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  9. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  10. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  11. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  12. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. Last author DOI 10.1177/00031348211011129↗
  13. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection. Last author DOI 10.1177/0003134821991962↗
  14. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  15. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. Last author DOI 10.1016/j.jss.2020.07.073↗
  16. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  17. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  18. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  19. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-020-08717-x↗
  20. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  21. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08087-z↗
  22. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  23. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  24. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  25. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  26. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Co-author DOI 10.1093/annonc/mdx180↗
  27. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Co-author DOI 10.1093/annonc/mdx273↗
  28. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. First author DOI 10.1200/jco.2016.70.2134↗
  29. Surgery for Pancreatic Cancer. Co-author DOI 10.1016/j.hoc.2015.04.001↗
  30. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 21 shared papers, 2015–2026 · strength 2.12
  2. Jonathan Andrew Nowak · 14 shared papers, 2017–2026 · strength 1.51
  3. Douglas Adam Rubinson · 14 shared papers, 2015–2026 · strength 1.39
  4. Stanley W. Ashley · 5 shared papers, 2021–2025 · strength 1.14
  5. Kimberly J. Perez · 9 shared papers, 2017–2026 · strength 1.03
  6. Andrew J. Aguirre · 10 shared papers, 2018–2026 · strength 1.02
  7. Joseph Douglas Mancias · 7 shared papers, 2017–2026 · strength 0.97
  8. Chen Yuan · 11 shared papers, 2015–2024 · strength 0.93
  9. George Molina · 5 shared papers, 2020–2026 · strength 0.89
  10. Kimmie Ng · 10 shared papers, 2015–2024 · strength 0.87
  11. James M. Cleary · 6 shared papers, 2021–2026 · strength 0.80
  12. Jiping Wang · 6 shared papers, 2020–2024 · strength 0.76
  13. Harshabad Singh · 5 shared papers, 2022–2026 · strength 0.72
  14. Andressa Dias Costa · 7 shared papers, 2020–2024 · strength 0.72
  15. Stephanie K. Dougan · 4 shared papers, 2022–2026 · strength 0.65
  16. Weizheng Ren · 3 shared papers, 2021–2022 · strength 0.64
  17. Vicente Morales‐Oyarvide · 8 shared papers, 2017–2023 · strength 0.63
  18. Albert C. Koong · 7 shared papers, 2017–2023 · strength 0.55
  19. Richard Francis Dunne · 7 shared papers, 2017–2023 · strength 0.55
  20. Margaret M. Kozak · 7 shared papers, 2017–2023 · strength 0.55
  21. Daniel Tandel Chang · 7 shared papers, 2017–2023 · strength 0.55
  22. Aram F. Hezel · 7 shared papers, 2017–2023 · strength 0.55
  23. Ana Babić · 6 shared papers, 2017–2024 · strength 0.53
  24. Andrea J. Bullock · 6 shared papers, 2017–2024 · strength 0.51
  25. Sara A. Väyrynen · 5 shared papers, 2021–2023 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.